SuperworthPfizer Inc. PFE
Drug Manufacturers - General, Healthcare
$28.00
+1.82%
- Market cap
- $159.6B
- PE
- 36.8×
- 10y median 16.3×
- Forward PE
- Price to sales
- 2.5×
- EV/EBIT
- 13.8×
- Revenue, 12 months
- $63.7B
- −0% on a year ago
- Net margin
- 6.8%
- Free cash flow yield
- 6.9%
Pfizer trades at 36.8× trailing earnings, pricier than 96% of the last ten years. Revenue was $63.7B over the last twelve months, down 0% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $14.6B | $14.9B | $13.3B | $17.7B | $17.8B+22% | $13.7B−8% | $14.7B+10% | $16.7B−6% | $17.6B−1% | $14.5B+5% | $15B+3% | |
| Cost of revenue | $7.6B | $3.4B | $3.3B | $5.3B | $5.9B−22% | $2.8B−16% | $3.8B+15% | $4.2B−21% | $5.3B−11% | $3.5B+25% | $4.1B+8% |
| Gross profit | $7B | $11.5B | $10B | $12.4B | $11.9B+69% | $10.9B−6% | $10.9B+9% | $12.5B+0% | $12.3B+4% | $10.9B+0% | $10.9B+1% |
| R&D | $2.8B | $2.5B | $2.7B | $2.6B | $3B+8% | $2.2B−12% | $2.5B−8% | $2.5B−2% | $3.2B+6% | $2.5B+13% | $2.8B+13% |
| SG&A | $4.6B | $3.5B | $3.7B | $3.2B | $4.3B−7% | $3B−13% | $3.4B−8% | $3.2B−2% | $4.2B−3% | $3B−2% | $3.4B−0% |
| −$1.3B | $4.6B | $1.9B | $5B | $5.7B | $4.6B+1% | $3.6B+90% | $3.5B−29% | $3.7B−36% | $4B−13% | $4.7B+32% | |
| Interest expense | $689M | $790M | $778M | $783M | $739M+7% | $654M−17% | $654M−16% | $652M−17% | $711M−4% | $668M+2% | $667M+2% |
| Pre-tax income | −$4.1B | $3.4B | −$103M | $4.7B | −$10M−100% | $2.8B−19% | $3B | $3.3B−29% | −$1.6B+16320% | $3.2B+14% | −$653M |
| −$795M | $293M | −$134M | $234M | −$421M−47% | −$189M | $141M | −$216M | −$2M−100% | $461M | −$407M | |
| Net income | −$3.4B | $3.1B | $41M | $4.5B | $410M | $3B−5% | $2.9B+6998% | $3.5B−21% | −$1.6B | $2.7B−9% | −$248M |
| −$0.60 | $0.55 | $0.01 | $0.78 | $0.07 | $0.52−6% | $0.51+5000% | $0.62−21% | −$0.29 | $0.47−10% | −$0.04 | |
| 5.6B | 5.7B | 5.7B | 5.7B | 5.7B+1% | 5.7B+0% | 5.7B+0% | 5.7B+0% | 5.7B−0% | 5.7B+0% | 5.7B−0% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times Pfizer's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PFEPfizer Inc. | $159.6B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| AMGNAmgen Inc. | $223.3B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| MRKMerck & Co., Inc. | $352.3B | 114× | 25.7× | 5.3× | +5% | 4.8% | |
| ABBVAbbVie Inc. | $479.5B | 76.7× | 27.5× | 7.4× | +10% | 9.8% | |
| JNJJohnson & Johnson | $622.8B | 29.9× | 24.2× | 6.4× | +8% | 21.5% | |
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| LLYEli Lilly and Company | $1.1T | 39.9× | 41.3× | 14.0× | +50% | 33.5% | |
| Peer median | $352.3B | 39.3× | 24.2× | 5.9× | +8% | 18.9% |
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .